Table 2. Analysis of signalling pathways significantly differentially expressed (P<0.05, corrected for multiple testing) between UKF-NB-4Hi and UKF-NB-4HiGCV cells and UKF-NB-4 in data sets of neuroblastoma patients27, 28 PANTHER pathway analysis.
| Pathway | Oberthuer et al.27,a | Asgharzadeh et al.28,b |
|---|---|---|
| |
Death/relapse from disease vs no relapse rankc (P-value) |
Relapse vs no relapse rankc (P-value) |
| Wnt signalling | 14 (2.33 × 10−3) | 1 (4.13 × 10−14) |
| Ras pathway | 4 (6.70 × 10−7) | 14 (1.58 × 10−4) |
| Ubiquitin proteasome pathway | 44 (4.82 × 10−1) | 15 (1.84 × 10−4) |
| Cadherin signalling pathway | 76 (1.00 × 100) | 23 (4.44 × 10−3) |
| Parkinson disease | 9 (2.49 × 10−4) | 27 (1.49 × 10−2) |
| Angiogenesis | 1 (5.60 × 10−13) | 2 (1.31 × 10−9) |
| Integrin signalling pathway | 10 (2.67 × 10−4) | 11 (1.63 × 10−5) |
| EGF receptor signalling pathway | 11 (5.11 × 10−4) | 6 (4.90 × 10−7) |
| PDGF signalling pathway | 3 (4.53 × 10−8) | 4 (2.74 × 10−8) |
| p53 pathway | 5 (5.57 × 10−6) | 8 (8.60 × 10−7) |
| Huntington disease | 42 (4.34 × 10−1) | 3 (2.15 × 10−8) |
| p53 pathways feedback loops 2 | 6 (6.63 × 10−6) | 39 (1.18 × 10−1) |
| Cytoskeletal regulation by Rho GTPase | 86 (1.00 × 100) | 18 (4.98 × 10−4) |
Abbreviations: EGF, epidermal growth factor; PDGF, platelet-derived growth factor.
a
21 out of 153 pathways were significantly differentially regulated (P<0.05).
b
32 out of 153 pathways were significantly differentially regulated (P<0.05).
c
Pathways were ranked according to their P-values for the comparison of non-favourable vs favourable outcome with the lowest P-value being rank 1.